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Gender Differences in Atherosclerotic Cardiovascular Disease (ASCVD)
====================================================================

There are substantial sex/gender differences in the prevalence and burden of ASCVD^[@bib1])^. George *et al.* evaluated the age and sex distribution of 60,155 incidences in men and 54,704 in women representing the initial presentation of a wide range of 12 major cardiovascular diseases, showing that myocardial infarction, but not unstable and stable angina, predominantly developed in men aged 30--39, 40--49, 50--59, and 60--69 years^[@bib1])^. The prevalence of traditional ASCVD risk factors and their differential impact in men and women, as well as the emerging and nontraditional risk factors, may contribute to the gender differences in ASCVD incidence^[@bib2])^. However, understanding the mechanisms leading to different outcomes in men and women remains to be elucidated. Given the evidence that experimental studies consistently demonstrate that estrogen has beneficial physiological effects on the vascular endothelium at cellular and molecular levels, it is imperative to clarify the precise mechanism of how the depletion of estrogen causes vascular derangement in women after menopause^[@bib3])^.

Vascular Senescence, SIRT1, and ASCVD
=====================================

Aging-induced functional and structural changes of vasculatures contribute to the pathogenesis of a wide range of age-related diseases, including ASCVD. Cellular senescence is a fundamental aging process wherein cells, including vascular endothelial and smooth muscle cells (vascular senescence^[@bib4])^), permanently withdraw from the cell cycle in response to a range of endogenous and exogenous stressors and undergo distinctive phenotypic alterations, including profound pro-inflammatory secretome changes^[@bib5])^.

Activation of SIRT1, a homolog of the yeast lifespan regulator Sir2, was reported to prolong the lifespan of rodents, whereas overexpression of SIRT1 in vascular smooth muscle (VSMC) or vascular endothelial cells was reported to suppress senescence and extend the survival of these cells^[@bib6])^. It has been suggested that SIRT1 is protective for vascular senescence through the activation of endothelial nitric oxide synthase (eNOS), inhibition of reactive oxygen species (ROS), inflammation, and DNA damage^[@bib7])^. Donato *et al.* indicated that reductions in SIRT-1 and eNOS activities play essential roles in vascular endothelial dysfunction with aging in both mice and human^[@bib8])^.

Underlying Mechanisms of Gender Difference in ASCVD: Estrogen, SIRT1, and eNOS
==============================================================================

Although protective roles of SIRT1 against vascular senescence and atherosclerosis have been reported, gender differences in the roles of SIRT1 in these conditions remain unknown. In this issue, Sasaki *et al.* elegantly indicated the roles of estrogen in SIRT1-associated vascular senescence and atherosclerosis^[@bib9])^. First, the authors demonstrated that vascular senescence and the formation of atherosclerotic plaque were facilitated in ovariectomized ApoE knockout (ApoE-KO) mice, concomitantly with a decrease in vascular SIRT1 expression. Second, administration of 17*β*-estradiol (E2) restored SIRT1 expression and vascular senescence as well as development of atherosclerosis in the mice, which was cancelled by a specific SIRT1 and SIRT2 inhibitor (sirtinols). Third, selective estrogen receptor modulator (SERM)/estrogen receptor agonist-antagonist (ERAA) mimicked the beneficial effects of E2 by inducing anti-senescence and anti-atherosclerosis through SIRT1 activation. Collectively, the authors concluded that SIRT1 plays a crucial role in estrogen in protecting arteries from senescence and atherosclerosis.

Among the seven members of the mammal sirtuin family, from SIRT1 to SIRT7, each has different tissue specificity, localization of subcellular activity, and target molecules^[@bib6])^. It is well known that Sirt1 activates eNOS and genetically engineered mouse models demonstrated that Sirt1 exerts atheroprotective effects by activating eNOS or by diminishing NFkB activity in endothelial cells and macrophages^[@bib6])^. Sirt3, as well as Sirt4 and Sirt5, is located in the mitochondria, and the protective effects of caloric restriction on cellular senescence depend on the presence of Sirt3, which increases the ratio of glutathione to glutathione disulfide. Mitochondrial Sirt3 drives the TCA (tricarboxylic acid) cycle, ß-oxidation, and oxidative phosphorylation, thus maintaining metabolic homeostasis and preventing the development of risk factors associated with the metabolic syndrome. Moreover, Sirt3 also carries out deacetylation and consecutive activation of superoxide dismutase 2 (SOD), mediating antioxidative protection and improving endothelial dysfunction.

Sasaki *et al.* found that administration of 17*β*-estradiol (E2) or SERM/ERAA restored SIRT1 expression but did not change SIRT3 expression in their protective role for vascular senescence and development of atherosclerosis. Therefore, it is considered that the actions of 17*β*-estradiol (E2) or SERM/ERAA can be exerted primarily by interactions of eNOS and SIRT1. Estrogens employ their physiological effects by binding with three estrogen receptors, ER*α*, ER*β*, and an orphan G-protein-coupled estrogen receptor, which differentially modulate gene expression and the protein levels in a tissue-specific manner^[@bib3])^. It has been reported that ER*α* expression modulated by estrogen in endothelial cells is linked to eNOS activation (phosphorylated-eNOS-Ser1177)^[@bib3])^.

SERMs/ERAAs have been used in the prevention and treatment of postmenopausal bone fractures related to osteoporosis or to breast cancer^[@bib10])^. SERMs/ERAAs include antagonist (tamoxifen) and agonists (raloxifene, ospemifene, arzoxifene, lasofoxifene, toremifene, and conjugated estrogen/bazedoxifene)^[@bib10])^. Sasaki *et al.* found that conjugated estrogen/bazedoxifene activates SIRT1 and prevents atherosclerotic plaque formation. Bazedoxifene is one of new third-generation SERMs/ERAAs and prevents bone loss in postmenopausal women at risk of osteoporosis through binding to both Er*α* and ER*β*. It is suggested that SERMs/ERAAs have potential as alternative therapeutic agents for atherosclerosis. Future experimental studies and clinical evidence conducted to show links among estrogen (SERM/ERAA), SIRT1, and eNOS may give us a new preventive tool for ASCVD. Possible underlying mechanisms of gender differences in ASCVD including current discussion in estrogen, SIRT1, and eNOS are shown in **[Fig. 1](#F1){ref-type="fig"}**.
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